Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SKRR Exploration Inc. V.SKRR

Alternate Symbol(s):  SKKRF

SKRR Exploration Inc. is a Canada-based precious metal explorer with properties in Saskatchewan mining jurisdictions. The Company's primary exploration focus is its three gold properties on the Trans-Hudson Corridor in Saskatchewan. The Company’s projects include Nickel Peak Group, Carp River, Manson Bay, Father Lake, Irving, Olson, Ithingo and Cathro. The Carp River property, comprised of five contiguous mineral claims totaling 5,606.48 hectares (ha), is located immediately north of the hamlet of Stony Rapids in the province of Saskatchewan. The 4,293 ha Manson Bay Project is located 40 kilometers (Km) northwest of Flin Flon, Manitoba’s historic mining center and four kilometers southwest of the Schotts Lake Copper-Zinc Deposit in Saskatchewan. The Father Lake property is located 40 km northeast of the hamlet of Stony Rapids in the province of Saskatchewan. The Ithingo Project consists of 12 contiguous mineral claims comprising an overall land package of approximately 2,849 hectares.


TSXV:SKRR - Post by User

Bullboard Posts
Post by DCArnoldon May 04, 2001 6:53pm
351 Views
Post# 3700425

ROBTV interview May 3rd

ROBTV interview May 3rdROBTV interview transcript, May 3rd Announcer: Biomira shares leaped 17% in today's trading on the TSE. The Edmonton based developer of cancer treatments announced a deal with Germany's Merck. Together the companies plan to develop and market Biomira's key products. Dr. Alex McPherson is Biomira's President and CEO, he's in New York today and he joins us now to discuss the announcement. Good afternoon. Dr. McPherson: Good afternoon Janice. Announcer: Well, you said the value of this fifteen year deal nears $150 million. Can you break down where that money is going to come from? Dr. McPherson: Well the breakdown is going to come from upfront payments that will be part equity and part cash, in addition to that there will be milestone payments, licensing fees and royalties which in the aggregate will amount to in excess of $150 million US. Announcer: Of the equity component, what percentage stake will Merck Germany now have in Biomira? Dr. McPherson: They'll take an equity stake which will be something less than 5% of our outstanding shares. Announcer: Any plans to increase that? Dr. McPherson: They have the opportunity, of course, as anybody does, through market acquisition of shares and they are looking at the possibility of acquiring up to something in excess of 19 but less than 20% of shares. They'll be doing that however through market acquisition not through treasury. Announcer: Dr. McPherson, you looked at a number of companies before deciding to partner with Merck Germany, what was it about this company that seems to work well for Biomira? Dr. McPherson: Two things Janice. The first was that we got the opportunity to participate in a co-development and co-promotion program for our two lead candidates in North America, the USA and Canada. So that we are able to revenue share which is an enormous improvement, in terms of return on investment for our shareholders, as compared to a straight royalty share. And secondly we found that the company had an enormously compatible culture with us. They are EMD, which is the wholly owned subsidiary of Merck of Germany, is the company that we'll be working most closely with in relation to going forward with the oncology program and they're very entrepreneurial. Their senior management has had substantial industrial experience, mainly with Astra-Zeneca and we believe that that experience along with our background in research and development and the attitudes and so forth of the companies are exceptional. Announcer: Now, this co-promotion arrangement, as opposed to strictly a royalty agreement, would you say one is riskier than the other? Dr. McPherson: Well, of course, yes. Royalty agreements, you basically sit back and put the check in the bank. On the other hand a co-promotion deal and a co-marketing deal allows the company to forward integrate and become a more mature company with a view to eventually bringing other products onstream for which we can provide marketing, sales and distribution capability. It's important, as I say often to people in our company that it's important that you know what you don't know and there are certain things about marketing, sales and distribution that we don't know and we'd like to learn from somebody who does, such as Merck KGaA. Announcer: Now, your R & D expenditures were $11 million in Q1, that's up from $8.4 million in the year earlier, would you say that there was a sense of urgency in trying to get this partnership done? Dr. McPherson: Well, if negotiating over about an eighteen month period is a sense of urgency then I guess that's a sense of urgency but this has been a long time coming and we've been very patient because we wanted the right deal for our investors and we think we've acquired it. Announcer: Now, your Theratope vaccine is a treatment for breast cancer, when do you expect it to reach the commercial market? Dr. McPherson: Well, this is a product which has got several analyses, the last analysis which is to look at survival as the endpoint, will start in the third quarter of 2003 and if successful, in terms of its statistical differences between the treatment and the control group, will be launched towards the end of 2004. It is possible if we are successful in showing important differences in the interim analysis to potentially have the product launched in the latter part of 2003 if the second analysis is positive. Indeed, it might even be possible to have the product launched in the latter part of 2002 if the time to progression endpoint which will be looked at in the third quarter of this year was strikingly significant. Announcer: On the financial side, you had a net loss of operations of $11.9 million in Q1, can you give us a rough timeline of profitability for your company? Dr. McPherson: Well that entirely depends upon the success of launching the two products that we are currently talking about, Theratope and BLP25, but certainly the expectation is that profitability would occur after launch of the product. As I've just indicated Theratope may be as late as the fourth quarter of 2004 or as early, and I must admit in an unusual circumstance, as early as the fourth quarter of 2002. Announcer: Very quickly, sir, we have about 20 seconds left, your shares got a really nice boost today, what have investors built into this stock price? Dr. McPherson: Well I think that they've built into the stock price the fact that we have got basically the kind of alliance that they want, a co-promotion, co-marketing deal with substantial cash payments related to the alliance. Announcer: Dr. McPherson, thank you so much for taking the time to speak with us today. Dr. McPherson: You're welcome. Thank you, Janice. Announcer: Alex McPherson, President and CEO of Biomira, Inc. joined us from New York.
Bullboard Posts